Pitavastatin and carbohydrate metabolism: what is the evidence?

References

• Cholesterol Treatment Trialists C, Fulcher J, O’Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–1405.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Mikhailidis DP. Statins and heart failure. Angiology. 2008;59(2 Suppl):58S–61S.
   Google Scholar
• Filippatos TD, Elisaf MS. Effects of ezetimibe/simvastatin combination on metabolic parameters. Int J Cardiol. 2016;202:273–274.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Rizos CV, Elisaf MS, et al. Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? Rev Diabet Stud. 2013;10(2–3):171–190.
   PubMedGoogle Scholar
• Agouridis AP, Tsimihodimos V, Filippatos TD, et al. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids. 2011;46(6):521–528.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011;12(12):1945–1958.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Statin-ezetimibe combination therapy In diabetic individuals. Angiology. 2015. [ Epub ahead of print].
   PubMedGoogle Scholar
• Iwere RB, Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(3):363–371.
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Filippatos TD, Mikhailidis DP, et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis. 2007;195(1):7–16.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Safety considerations with fenofibrate/simvastatin combination. Expert Opin Drug Saf. 2015;14(9):1481–1493.
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–2564.
   PubMed Web of Science ®Google Scholar
• Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014;57(12):2444–2452.
   PubMed Web of Science ®Google Scholar
• Kohli P, Waters DD, Nemr R, et al. Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. J Am Coll Cardiol. 2015;65(4):402–404.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742.
   PubMed Web of Science ®Google Scholar
• Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385(9965):351–361.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Kostapanos MS, Elisaf MS. Statins and their increased risk of inducing diabetes. Expert Opin Drug Saf. 2015;14(12):1835–1844.
   PubMed Web of Science ®Google Scholar
• Bellia A, Rizza S, Lombardo MF, et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis. 2012;223(1):197–203.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Agouridis AP, Elisaf MS. Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Diabetologia. 2015;58(8):1960–1961.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Rizos CV, Elisaf MS. Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. Drug Saf. 2014;37(7):481–500.
   PubMed Web of Science ®Google Scholar
• Kei A, Liberopoulos E, Elisaf M. Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia. World J Diabetes. 2013;4(6):365–371.
   PubMedGoogle Scholar
• Kostapanos MS, Liamis GL, Milionis HJ, et al. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol. 2010;8(5):612–631.
   PubMed Web of Science ®Google Scholar
• Nowis D, Malenda A, Furs K, et al. Statins impair glucose uptake in human cells. BMJ Open Diabetes Res Care. 2014;2(1):e000017.
   PubMedGoogle Scholar
• Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006;49(8):1881–1892.
   PubMed Web of Science ®Google Scholar
• Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.. Fundam Clin Pharmacol. 2005;19(1):117–125.
   PubMed Web of Science ®Google Scholar
• Baker WL, Talati R, White CM, et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87(1):98–107.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–571.
   PubMed Web of Science ®Google Scholar
• Teramoto T, Shimano H, Yokote K, et al. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother. 2010;11(5):817–828.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Orsoni A, Robillard P, et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin. 2014;30(5):775–784.
   PubMed Web of Science ®Google Scholar
• Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2003;21(3):199–215.
   PubMed Web of Science ®Google Scholar
• Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005;59(2):239–252.
   PubMed Web of Science ®Google Scholar
• Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84(3):413–428.
   PubMed Web of Science ®Google Scholar
• Shang D, Deng S, Yao Z, et al. The effect of food on the pharmacokinetic properties and bioequivalence of two formulations of pitavastatin calcium in healthy Chinese male subjects. Xenobiotica. 2015;46(1):34–39.
   PubMed Web of Science ®Google Scholar
• Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7(3):138–144.
   PubMedGoogle Scholar
• Choi SH, Lim S, Hong ES, et al. PROPIT: a PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome. Clin Endocrinol (Oxf). 2015;82(5):670–677.
   PubMed Web of Science ®Google Scholar
• Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30(6):1089–1101.
   PubMed Web of Science ®Google Scholar
• Cho Y, Choe E, Lee YH, et al. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metabolism. 2015;64(4):482–488.
   PubMed Web of Science ®Google Scholar
• Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015;241(2):409–418.
   PubMed Web of Science ®Google Scholar
• Mita T, Nakayama S, Abe H, et al. Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia. J Diabetes Investig. 2013;4(3):297–303.
   PubMed Web of Science ®Google Scholar
• Liu PY, Lin LY, Lin HJ, et al. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). PLoS One. 2013;8(10):e76298.
   PubMed Web of Science ®Google Scholar
• Gumprecht J, Gosho M, Budinski D, et al. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab. 2011;13(11):1047–1055.
   PubMed Web of Science ®Google Scholar
• Daido H, Horikawa Y, Takeda J. The effects of pitavastatin on glucose metabolism in patients with type 2 diabetes with hypercholesterolemia. Diabetes Res Clin Pract. 2014;106(3):531–537.
   PubMed Web of Science ®Google Scholar
• Chakraborti CK. Role of adiponectin and some other factors linking type 2 diabetes mellitus and obesity. World J Diabetes. 2015;6(15):1296–1308.
   PubMed Web of Science ®Google Scholar
• Arnaboldi L, Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl. 2015;16:1–27.
   PubMed Web of Science ®Google Scholar
• Kurogi K, Sugiyama S, Sakamoto K, et al. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD studyl. J Cardio. 2013;62(2):87–94.
   PubMed Web of Science ®Google Scholar
• Nomura S, Inami N, Shouzu A, et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets. 2009;20(1):16–22.
   PubMed Web of Science ®Google Scholar
• Ishihara Y, Ohmori K, Mizukawa M, et al. Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis. 2010;212(1):131–138.
   PubMed Web of Science ®Google Scholar
• Tsubouchi H, Inoguchi T, Sonta T, et al. Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med. 2005;39(4):444–452.
   PubMed Web of Science ®Google Scholar
• Fujii T, Onimaru M, Yonemitsu Y, et al. Statins restore ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not via PDGF-BB expression. Am J Physiol Heart Circ Physiol. 2008;294(6):H2785–H2791.
   Google Scholar
• Matsumoto M, Tanimoto M, Gohda T, et al. Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice. Metabolism. 2008;57(5):691–697.
   PubMed Web of Science ®Google Scholar
• Mizukami H, Inaba W, Takahashi K, et al. Augmented reduction of islet β-cell mass in Goto-Kakizaki rats fed high-fat diet and its suppression by pitavastatin treatment. J Diabetes Investig. 2012;3(3):235–244.
   PubMed Web of Science ®Google Scholar
• Kakuda H, Kobayashi J, Nakato M, et al. Short-term effect of pitavastatin treatment on glucose and lipid metabolism and oxidative stress in fasting and postprandial state using a test meal in Japanese men. Cholesterol. 2013;2013:314170.
   PubMedGoogle Scholar
• Fukuda K, Matsumura T, Senokuchi T, et al. Statins meditate anti-atherosclerotic action in smooth muscle cells by peroxisome proliferator-activated receptor-γ activation. Biochem Biophys Res Commun. 2015;457(1):23–30.
   PubMed Web of Science ®Google Scholar
• Kawashiri M-A, Nohara A, Tada H, et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther. 2008;83(5):731–739.
   PubMed Web of Science ®Google Scholar
• Nomura S, Shouzu A, Omoto S, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res. 2008;122(1):39–45.
   PubMed Web of Science ®Google Scholar
• Inami N, Nomura S, Shouzu A, et al. Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb. 2007;36(1):1–8.
   PubMedGoogle Scholar
• Banach M, Serban C, Ursoniu S, et al. Statin therapy and plasma coenzyme Q10 concentrations–a systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res. 2015;99:329–336.
   PubMed Web of Science ®Google Scholar
• Tarry-Adkins JL, Fernandez-Twinn DS, Madsen R, et al. Coenzyme Q10 prevents insulin signaling dysregulation and inflammation prior to development of insulin resistance in male offspring of a rat model of poor maternal nutrition and accelerated postnatal growth. Endocrinology. 2015;156(10):3528–3537.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Kishimoto J, Ito C, et al. Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int. 2011;2(3):134–140.
   Google Scholar
• Odawara M, Yamazaki T, Kishimoto J et al. Effect of pitavastatin on the incidence of diabetes in Japanese individuals with impaired glucose tolerance. 2015 [cited 2016 Mar 7]. Available from: https://distribute.m-anage.com/from.storage?image=XQl42zTOfqciza%252ffgIH06qRnRg53p84GB58voZSMp1LACl1lcTlEd1XZvJ7Vz6LFJk1ya5R9FT8Qv5MJyMH7%252bQ%253d%253d
   Google Scholar